The Evolving Management of Psoriatic Disease: A Guide for Managed Care and Specialty Pharmacy Professionals
Jointly provided by

This activity is supported by an independent educational grant from UCB.

You Are Invited to a CME/CE Live Webcast

The Evolving Management of Psoriatic Disease: A Guide for Managed Care and Specialty Pharmacy Professionals

The Live Webcasts have ended. An on-demand CE archive will be available in March.
Until then, please check out our website for more Free CE activites

  • Clinical trial data for existing and emerging psoriatic disease therapies
  • Collaborative treatment decision-making, and treatment optimization via use of specialty pharmacy support services.
John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, PLLC
Jamie McConaha, PharmD, NCTTP, BCACP, CDE
Associate Professor of Pharmacy Practice
Duquesne University Mylan School of Pharmacy
Michael Zeglinski, RPh
Optum Specialty & Infusion Pharmacies
  • This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, registered nurses, and other managed health care professionals.

Psoriasis and psoriatic arthritis present a significant clinical and humanistic burden to patients and managed care/specialty pharmacy organizations. Patients diagnosed with psoriatic disease are subject to increased mortality and functional disability which can lead to significant impairment of QoL and increased use of health care resources. Fortunately, there has been a marked increase in the number of safe and effective therapies to the disease. As a result, managed care and specialty pharmacy decision makers are challenged to match patients with the most appropriate therapeutic option. This task is complicated by the high prevalence of multiple chronic comorbid conditions as well as poor adherence to prescribed therapy; all of which must be addressed in order to achieve successful outcomes. The pathologic complexity of psoriatic disease and its comorbidities often requires collaborative multidisciplinary care. Improved awareness of therapeutic options available to manage the spectrum of pathologic challenges confronted by patients with psoriatic disease will enable managed care and specialty pharmacy professionals to improve patient quality of life and clinical outcomes.


At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Assess the latest therapeutic developments for the treatment of psoriatic disease
  • Evaluate the challenges of treatment for patients with psoriatic disease and comorbidities
  • Employ timely referral and collaborative, multidisciplinary management of psoriatic disease patients
  • Utilize treatment optimization approaches to balance costs with improved outcomes in psoriatic disease management
Pre-Activity Learning Assessment and Opening Comments/Overview
Michael Zeglinski, RPh
Assessing the Latest Clinical Evidence for Current and Emerging Therapies
Jamie McConaha, PharmD, NCTTP, BCACP, CDE
Integration of Recent Clinical Findings with Medical Management Approaches in Psoriatic Disease
John Fox, MD, MHA
Patient Management Strategies to Enhance Psoriatic Disease Outcomes
Michael Zeglinski, RPh
Audience Q&A Session
Key Takeaways and Closing Comments; Post-Activity Assessment and Evaluation
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2484-L01-P
Type of Activity: Application

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

If you have any questions, please call (215) 619-8812 or email